These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 25806180)

  • 21. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
    Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
    Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.
    Lara MS; Holland WS; Chinn D; Burich RA; Lara PN; Gandara DR; Kelly K; Mack PC
    Clin Lung Cancer; 2017 May; 18(3):281-285. PubMed ID: 28038979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
    Liang H; Wang M
    Onco Targets Ther; 2020; 13():2491-2510. PubMed ID: 32273721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
    Sano T; Takeuchi S; Nakagawa T; Ishikawa D; Nanjo S; Yamada T; Nakamura T; Matsumoto K; Yano S
    Int J Cancer; 2013 Jul; 133(2):505-13. PubMed ID: 23319394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
    Moosavi F; Giovannetti E; Saso L; Firuzi O
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.
    Rothenberger NJ; Stabile LP
    Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28441771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.
    Huang G; Liu X; Jiang T; Cao Y; Sang M; Song X; Zhou B; Qu H; Cai H; Xing D; Mao Y; Lin G; Liu X; Zheng X
    Am J Cancer Res; 2023; 13(9):4145-4162. PubMed ID: 37818074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
    Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
    J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
    Kang XH; Wang LF; Cao F; Fan FT; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
    Sylvester PW
    Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
    Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition.
    Shi X; Wang M; Zhang Y; Guo X; Liu M; Zhou Z; Zhao Y; He R; Gao Y; Liu Y; Pan S; Zhou M; Zhao C; Yin T; Li X; Wang H; Yang J; Zhu F; Li M; Qin R
    EBioMedicine; 2022 Dec; 86():104352. PubMed ID: 36371988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.
    Landi L; Minuti G; D'Incecco A; Cappuzzo F
    Curr Opin Oncol; 2013 Mar; 25(2):130-6. PubMed ID: 23385860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant
    Al-Ghabkari A; Huang B; Park M
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.